{"url_path":"/sec/kytx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-219397-index.html","accession_number":"0001193125-26-219397","cik":"0001994702","ticker":"KYTX","issuer_name":"Kyverna Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-219397-index.html","primary_entity_key":"0001994702","primary_entity_name":"Kyverna Therapeutics, Inc."},"word_count":278,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\n(a) Unregistered Sales of Equity Securities\n\nNone.\n\n(b) Use of Proceeds from Initial Public Offering\n\nOn February 12, 2024, we closed the IPO, pursuant to which we issued and sold 16,675,000 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 2,175,000 additional shares, at an initial public offering price of $22.00 per share.\n\nThe offer and sale of all of the shares of our common stock in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-276523), which was declared effective by the SEC on February 7, 2024. Following the sale of the above shares, the offering terminated. J.P. Morgan, Morgan Stanley, Leerink Partners and Wells Fargo Securities acted as joint book-running managers.\n\nWe received aggregate gross proceeds from the IPO of $366.9 million, or aggregate net proceeds of $336.2 million, inclusive of the full exercise by the underwriters of their option to purchase additional shares, after deducting underwriting discounts and commissions and estimated other offering costs totaling $30.7 million. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to (i) our directors or officers or their associates, (ii) persons owning 10% or more of our common stock or (iii) any of our affiliates.\n\nThere has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 8, 2024.\n\n(c) Issuer Repurchases of Equity Securities\n\n100\n\n \n\nNone."}